Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4SCAR19 + 4SCAR38
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
4SCAR19 + 4SCAR38 is a **combination cell therapy** comprising two fourth-generation chimeric antigen receptor (CAR) T cell products: 4SCAR19 and 4SCAR38. Each product consists of autologous T cells engineered to express a CAR construct targeting specific surface antigens. 4SCAR19 targets CD19, a well-established B cell marker, and 4SCAR38 targets CD38, an antigen expressed on malignant plasma cells as well as other B cell malignancies. Both constructs incorporate multiple costimulatory domains (including CD28 and CD27) and an inducible safety switch (iCasp9) to enhance efficacy and allow controlled elimination of the cells in case of severe toxicity. The therapy is administered following lymphodepleting chemotherapy in patients with refractory or relapsed B-cell lymphoma or related malignancies. This approach aims to reduce the risk of antigen escape and relapse by targeting more than one antigen and overcoming resistance to single-antigen CAR-T treatment[3][5][9].
- Brand names
- 4SCAR19 + 4SCAR38
- Other names
- 4SCAR19 and 4SCAR38
02
Targets
CD38 (Cluster of Differentiation 38)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on 4SCAR19 + 4SCAR38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4SCAR19 + 4SCAR38.